Detoxification of 7-dehydrocholesterol fatal to Helicobacter pylori is a novel role of cholesterol glucosylation

Journal of Bacteriology

Volumn 195, Issue 2, 2013, Pages 359-367

  Shimomura, Hirofumi ^a   Hosoda, Kouichi ^a   Mcgee, David J ^b   Hayashi, Shunji ^a   Yokota, Kenji ^c   Hiraia, Yoshikazu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 DEHYDROCHOLESTEROL;

ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIOLYSIS; CGT GENE; DETOXIFICATION; GLYCOSYLATION; HELICOBACTER PYLORI; NONHUMAN; PRIORITY JOURNAL;

BIOTRANSFORMATION; CELL MEMBRANE; DEHYDROCHOLESTEROLS; GENE DELETION; GLYCOSYLATION; HELICOBACTER PYLORI; MICROBIAL VIABILITY;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

EID: 84872169062     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.01495-12     Document Type: Article

References (34)

1. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terano S, Amagai K, Hayashi S, Asaka M, Japan Gast Study Group. 2008. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an openlabel, randomised controlled trial. Lancet 372:392-397.
2. Graham DY. 1991. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J. Gastroenterol. Hepatol. 6:105-113.
3. Marshall B, Warren JR. 1983. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet i:1273-1274.
4. Peek RM, Jr, Blaser MJ. 2002. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat. Rev. Cancer 2:28-37.
5. Peek RM, Jr, Crabtree JE. 2006. Helicobacter infection and gastric neoplasia. J. Pathol. 208:233-248.
6. Stolte M, Bayerdorffer E, Morgner A, Alpen B, Wundish T, Thiede C, Neubauer A. 2002. Helicobacter and gastric MALT lymphoma. Gut 50: III19-III24.
7. Uemura N, Okamoto S, Yamamoto S, Matsumura M, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. 2001. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345:784-789.
8. Wyatt JI, Dixon MF. 1988. Chronic gastritis-a pathogenetic approach. J. Pathol. 154:113-124.
9. Wunder C, Churin Y, Winau F, Warnecke D, Vieth M, Lindner B, Zähringer U, Mollenkopf HJ, Heinz E, Meyer TF. 2006. Cholesterol glucosylation promotes immune evasion by Helicobacter pylori. Nat. Med. 12:1030-1038.
10. McGee DJ, George AE, Trainor EA, Horton KE, Hildebrandt E, Testerman TL. 2011. Cholesterol enhances Helicobacter pylori resistance to antibiotics and LL-37. Antimicrob. Agents Chemother. 55: 2897-2904.
11. Lebrun A, Wunder C, Hildebrand J, Churin Y, Zähringer U, Lindner B, Meyer TF, Heinz E, Warnecke D. 2006. Cloning of a cholesterol-α- glucosyltransferase from Helicobacter pylori. J. Biol. Chem. 281:27765-27772.
12. Hirai Y, Haque M, Yoshida T, Yokota K, Yasuda T, Oguma K. 1995. Unique cholesteryl glucosides in Helicobacter pylori: composition and structural analysis. J. Bacteriol. 177:5327-5333.
13. Hosoda K, Shimomura H, Hayashi S, Yokota K, Oguma K, Hirai Y. 2009. Anabolic utilization of steroid hormones in Helicobacter pylori. FEMS Microbiol. Lett. 297:173-179.
14. Hosoda K, Shimomura H, Hayashi S, Yokota K, Hirai Y. 2011. Steroid hormones as bactericidal agents to Helicobacter pylori. FEMS Microbiol. Lett. 318:68-75.
15. Shimomura H, Hosoda K, Hayashi S, Yokota K, Oguma K, Hirai Y. 2009. Steroids mediate resistance to the bactericidal effect of phosphatidylcholines against Helicobacter pylori. FEMS Microbiol. Lett. 301:84-94.
16. Trainor EA, Horton KE, Savage PE, Testerman TL, McGee DJ. 2011. Role of the HefC efflux pump in Helicobacter pylori cholesterol-dependent resistance to ceragenins and bile salts. Infect. Immun. 79:88-97.
17. Javitt NB. 2004. Oxysterols: a new class of steroids with autocrine and paracrine functions. Trends Endocrinol. Metabol. 15:393-397.
18. Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, Salen G. 1994. Defective cholesterol biosynthesis associated with the Smith-Lemli- Opitz syndrome. N. Engl. J. Med. 330:107-113.
19. Björkhem I, Starck L, Andersson U, Lütjohann D, von Bahr S, Pikuleva I, Babiker A, Diczfalusy U. 2001. Oxysterols in the circulation of patients with the Smith-Lemli-Opitz syndrome: abnormal levels of 24S- and 27- hydroxycholesterol. J. Lipid Res. 42:366-371.
20. Jira PE, De Jong JGN, Janssen-Zijlstra FSM, Wendel U, Wevers RA. 1997. Pitfalls in measuring plasma cholesterol in the Smith-Lemli-Opitz syndrome. Clin. Chem. 43:129-133.
21. Merkens LS, Connor WE, Linck LM, Lin DS, Flavell DP, Steiner RD. 2004. Effects of dietary cholesterol on plasma lipoproteins in Smith- Lemli-Opitz syndrome. Pediatr. Res. 56:726-732.
22. Berstad K, Berstad A, Jr, Sjödahl R, Weberg R, Berstad A. 1992. Eosinophil cationic protein and phospholipase A2 activity in human gastric juice with emphasis on Helicobacter pylori status and effects of antacids. Scand. J. Gastroenterol. 27:1011-1017.
23. Orihara T, Wakabayashi H, Nakaya A, Fukuta K, Makimoto S, Naganuma K, Entani A, Watanabe A. 2001. Effect of Helicobacter pylori eradication on gastric mucosal phospholipid content and its fatty acid composition. J. Gastroenterol. Hepatol. 16:269-275.
24. Shimomura H, Hosoda K, Hayashi S, Yokota K, Hirai Y. 2012. Phosphatidylethanolamine of Helicobacter pylori functions as a steroid-binding lipid in the assimilation of free cholesterol and 3β-hydroxyl steroids into the bacterial cell membrane. J. Bacteriol. 194:2658-2667.
25. Chalker AF, Minehart HW, Hughes NJ, Koretke KK, Lonetto MA, Brinkman KK, Warren PV, Lupas A, Stanhope MJ, Brown JR, Hoffman PS. 2001. Systematic identification of selective essential genes in Helicobacter pylori by genome prioritization and allelic replacement mutagenesis. J. Bacteriol. 183:1259-1268.
26. Hildebrandt E, McGee DJ. 2009. Helicobacter pylori lipopolysaccharide modification, Lewis antigen expression, and gastric colonization are cholesterol- dependent. BMC Microbiol. 9:258-272. doi:10.1186/1471-2180-9-258.
27. Wang Y, Roos KP, Taylor DE. 1993. Transformation of Helicobacter pylori by chromosomal metronidazole resistance and by a plasmid with a selectable chloramphenicol resistance marker. J. Gen. Microbiol. 139: 2485-2493.
28. Junquera E, Peña L, Aicart E. 1998. Binding of sodium salicylate by β-cyclodextrin or 2,6-di-O-methyl-β-cyclodextrin in aqueous solution. J. Pharm. Sci. 87:86-90.
29. Yu Z, Cui M, Yan C, Song F, Liu Z, Liu S. 2007. Investigation of heptakis (2,6-di-O-methyl)-β-cyclodextrin inclusion complexes with flavonoid glucosides by electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 21:683-690.
30. Arima H, Yunomae K, Morikawa T, Hirayama F, Uekama K. 2004. Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl- β-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. Pharm. Res. 21:625-634.
31. Fukasawa M, Nishijima M, Itabe H, Takano T, Hanada K. 2000. Reduction of sphingomyelin level without accumulation of ceramide in Chinese hamster ovary cells affects detergent-resistant membrane do- mains and enhances cellular cholesterol efflux to methyl-betacyclodextrin. J. Biol. Chem. 275:34028-34034.
32. 2+ mobilization. Pharmacologist 44:A68.
33. Yamashita T, Yamaguchi T, Murakami K, Nagasawa S. 2001. Detergentresistant membrane domains are required for mast cell activation but dispensable for tyrosine phosphorylation upon aggregation of the highaffinity receptor for IgE. J. Biochem. 129:861-868.
34. Yunomae K, Arima H, Hirayama F, Uekama K. 2003. Involvement of cholesterol in the inhibitory effect of dimethyl-β-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett. 536:225-231.